• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.

    5/6/26 9:07:24 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care
    Get the next $MDLN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Medline Inc.

    (Name of Issuer)


    Class A common stock, par value $0.0001 per share

    (Title of Class of Securities)




    58507V107

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    58507V107


    1Names of Reporting Persons

    Hellman & Friedman Capital Partners X (Parallel), L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    74,496,172.00
    6Shared Voting Power

    7Sole Dispositive Power

    74,496,172.00
    8Shared Dispositive Power

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    74,496,172.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.9 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    58507V107


    1Names of Reporting Persons

    HFCP X (Parallel - A), L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    7,781,788.00
    6Shared Voting Power

    7Sole Dispositive Power

    7,781,788.00
    8Shared Dispositive Power

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,781,788.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    58507V107


    1Names of Reporting Persons

    Mend Partners II, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,176,227.00
    6Shared Voting Power

    7Sole Dispositive Power

    4,176,227.00
    8Shared Dispositive Power

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,176,227.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    58507V107


    1Names of Reporting Persons

    Mend Investment Holdings I, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    100,629,526.00
    6Shared Voting Power

    7Sole Dispositive Power

    100,629,526.00
    8Shared Dispositive Power

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    100,629,526.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.6 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    58507V107


    1Names of Reporting Persons

    Hellman & Friedman Investors X, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    187,083,713.00
    6Shared Voting Power

    7Sole Dispositive Power

    187,083,713.00
    8Shared Dispositive Power

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    187,083,713.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    19.8 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    58507V107


    1Names of Reporting Persons

    Mend Partners GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,176,227.00
    6Shared Voting Power

    7Sole Dispositive Power

    4,176,227.00
    8Shared Dispositive Power

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,176,227.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    58507V107


    1Names of Reporting Persons

    Mend Investment Holdings GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    100,629,526.00
    6Shared Voting Power

    7Sole Dispositive Power

    100,629,526.00
    8Shared Dispositive Power

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    100,629,526.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.6 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    58507V107


    1Names of Reporting Persons

    Hellman & Friedman Capital Partners X, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    100,629,526.00
    6Shared Voting Power

    7Sole Dispositive Power

    100,629,526.00
    8Shared Dispositive Power

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    100,629,526.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.6 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    58507V107


    1Names of Reporting Persons

    H&F Corporate Investors X, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    187,083,713.00
    6Shared Voting Power

    7Sole Dispositive Power

    187,083,713.00
    8Shared Dispositive Power

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    187,083,713.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    19.8 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Medline Inc.
    (b)Address of issuer's principal executive offices:

    3 Lakes Drive, Northfield, Illinois 60093
    Item 2. 
    (a)Name of person filing:

    This Amendment No. 1 ("Amendment") amends the initial statement on Schedule 13G (the "Schedule 13G") jointly filed on February 13, 2026 by the following persons (each a "Reporting Person" and collectively, the "Reporting Persons"): (i) Hellman & Friedman Capital Partners X (Parallel), L.P., a Cayman Islands exempted limited partnership ("HFCP X Parallel"); (ii) HFCP X (Parallel - A), L.P., a Delaware limited partnership ("HFCP X Parallel-A"); (iii) Mend Partners II, L.P., a Delaware limited partnership ("Mend Partners II"); (iv) Mend Investment Holdings I, L.P., a Delaware limited partnership ("Mend Investment I"); (v) Hellman & Friedman Investors X, L.P., a Cayman Islands exempted limited partnership ("Investors X GP"); (vi) Mend Partners GP, LLC, a Delaware limited liability company ("Mend GP"); (vii) Mend Investment Holdings GP, LLC, a Delaware limited liability company ("Mend Investment GP"); (viii) Hellman & Friedman Capital Partners X, L.P., a Cayman Islands exempted limited partnership ("HFCP X"); and (ix) H&F Corporate Investors X, Ltd., a Cayman Islands exempted company ("Investors X Ltd."). Investors X GP is the general partner of HFCP X Parallel and HFCP X Parallel-A. Mend GP is the general partner of Mend Partners II. Investors X GP is the managing member of Mend GP. Mend Investment GP is the general partner of Mend Investment I. HFCP X is the managing member of Mend Investment GP. Investors X GP is the general partner of HFCP X. Investors X Ltd. is the general partner of Investors X GP. Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Schedule 13G. Except as set forth herein, the Schedule 13G is unmodified.
    (b)Address or principal business office or, if none, residence:

    The principal business address of each of the Reporting Persons is c/o Hellman & Friedman LLC, 415 Mission Street, Suite 5700, San Francisco, CA 94105
    (c)Citizenship:

    See Item 2(a)
    (d)Title of class of securities:

    Class A common stock, par value $0.0001 per share
    (e)CUSIP No.:

    58507V107
    Item 4.Ownership
    (a)Amount beneficially owned:

    Item 4(a) of the Schedule 13G is hereby amended and restated as follows: The information contained in rows 5, 6, 7, 8, 9, 10, and 11 on each of the cover pages of this Amendment is incorporated by reference into this Item 4. As of March 31, 2026, the Reporting Persons may have been deemed to beneficially own an aggregate of 187,083,713 shares of the Class A common stock of Medline Inc. (the "Class A Common Stock"), consisting of: (i) 74,496,172 shares of the Class A Common Stock held by HFCP X Parallel, (ii) 7,781,788 shares of Class A Common Stock held by HFCP X Parallel-A, (iii) 4,176,227 shares of Class A Common Stock held by Mend Partners II, (iv) 19,310 shares of Class A Common Stock held by Mend Investment I, and (v) 100,610,216 shares of Class A Common Stock issuable to Mend Investment I upon exchange for an equal number of the common units of Medline Holdings L.P. (the "Common Units") held by Mend Investment I. The Common Units held by Mend Investment I are paired with an equal number of shares of the Class B common stock of Medline Inc. (the "Class B Common Stock"). Pursuant to the terms of an exchange agreement, dated as of December 16, 2025, holders of Common Units have the right to exchange their Common Units for shares of Class A Common Stock on a one-for-one basis, subject to customary conversion rate adjustments for stock splits, stock dividends and re-classifications. These exchange rights do not expire. Shares of the Class B Common Stock have no economic value and have one vote per share. One share of Class B Common Stock is issued for each Common Unit held. Upon an exchange of Common Units for shares of the Class A Common Stock, an equivalent number of shares of Class B Common Stock held by such holder will be automatically cancelled. Mend GP is the general partner of Mend Partners II and may, as a result, be deemed to beneficially own the 4,176,227 shares of Class A Common Stock beneficially owned by Mend Partners II. Mend Investment GP is the general partner of Mend Investment I and HFCP X is the managing member of Mend Investment GP and, as a result, each of Mend Investment GP and HFCP X may be deemed to beneficially own the 100,629,526 shares of Class A Common Stock beneficially owned by Mend Investment I. Investors X GP is the managing member of Mend GP and the general partner of each of HFCP X Parallel, HFCP X Parallel-A and HFCP X as, as a result, may be deemed to beneficially own an aggregate of 187,083,713 shares of Class A Common Stock beneficially owned by such entities. Investors X Ltd. is the general partner of Investors X GP and may, as a result, be deemed to beneficially own the 187,083,713 shares of Class A Common Stock beneficially owned by Investors X GP. A three-member board of directors of Investors X Ltd. has voting and investment discretion over the securities held by HFCP X Parallel, HFCP X Parallel-A, Mend Partners II., and Mend Investment I. Each of the members of the board of directors of Investors X Ltd. disclaims beneficial ownership of such shares.
    (b)Percent of class:

    Item 4(b) of the Schedule 13G is hereby amended and restated as follows: The ownership percentages reflected in this Schedule 13G are calculated based on (i) 845,611,435 shares of Class A Common Stock outstanding as reported in the Issuer's Final Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on March 6, 2026, following the underwriters' exercise in full of their option to purchase additional shares of Class A Common Stock, plus (ii) 100,610,216 shares of Class A Common Stock issuable to the Reporting Persons upon exchange of Common Units.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See row 5 on each of the cover pages of this Amendment.

     (ii) Shared power to vote or to direct the vote:

    See row 6 on each of the cover pages of this Amendment.

     (iii) Sole power to dispose or to direct the disposition of:

    See row 7 on each of the cover pages of this Amendment.

     (iv) Shared power to dispose or to direct the disposition of:

    See row 8 on each of the cover pages of this Amendment.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Hellman & Friedman Capital Partners X (Parallel), L.P.
     
    Signature:/s/ Jacob Best
    Name/Title:Jacob Best, Vice President of H&F Corporate Investors X, Ltd., See Exhibit 99.1
    Date:05/06/2026
     
    HFCP X (Parallel - A), L.P.
     
    Signature:/s/ Jacob Best
    Name/Title:Jacob Best, Vice President of H&F Corporate Investors X, Ltd., See Exhibit 99.1
    Date:05/06/2026
     
    Mend Partners II, L.P.
     
    Signature:/s/ Jacob Best
    Name/Title:Jacob Best, Vice President of H&F Corporate Investors X, Ltd., See Exhibit 99.1
    Date:05/06/2026
     
    Mend Investment Holdings I, L.P.
     
    Signature:/s/ Jacob Best
    Name/Title:Jacob Best, Vice President of H&F Corporate Investors X, Ltd., See Exhibit 99.1
    Date:05/06/2026
     
    Hellman & Friedman Investors X, L.P.
     
    Signature:/s/ Jacob Best
    Name/Title:Jacob Best, Vice President of H&F Corporate Investors X, Ltd., See Exhibit 99.1
    Date:05/06/2026
     
    Mend Partners GP, LLC
     
    Signature:/s/ Jacob Best
    Name/Title:Jacob Best, Vice President of H&F Corporate Investors X, Ltd., See Exhibit 99.1
    Date:05/06/2026
     
    Mend Investment Holdings GP, LLC
     
    Signature:/s/ Jacob Best
    Name/Title:Jacob Best, Vice President of H&F Corporate Investors X, Ltd., See Exhibit 99.1
    Date:05/06/2026
     
    Hellman & Friedman Capital Partners X, L.P.
     
    Signature:/s/ Jacob Best
    Name/Title:Jacob Best, Vice President of H&F Corporate Investors X, Ltd., See Exhibit 99.1
    Date:05/06/2026
     
    H&F Corporate Investors X, Ltd.
     
    Signature:/s/ Jacob Best
    Name/Title:Jacob Best, Vice President of H&F Corporate Investors X, Ltd., See Exhibit 99.1
    Date:05/06/2026
    Get the next $MDLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDLN

    DatePrice TargetRatingAnalyst
    3/11/2026$60.00Buy
    Citigroup
    2/5/2026$55.00Buy
    Tigress Financial
    1/21/2026$50.00 → $55.00Buy
    BTIG Research
    1/12/2026$48.00Buy
    Citigroup
    1/12/2026$38.00Neutral
    BNP Paribas Exane
    1/12/2026$50.00Overweight
    Analyst
    1/12/2026$50.00Overweight
    Piper Sandler
    1/12/2026$48.00Overweight
    Morgan Stanley
    More analyst ratings

    $MDLN
    SEC Filings

    View All

    Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement

    8-K - Medline Inc. (0002046386) (Filer)

    6/2/26 8:06:32 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    SEC Form 424B4 filed by Medline Inc.

    424B4 - Medline Inc. (0002046386) (Filer)

    5/26/26 4:05:33 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Medline Inc.

    EFFECT - Medline Inc. (0002046386) (Filer)

    5/22/26 12:15:23 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gic Private Ltd sold $289,480,090 worth of shares (10,204,351 units at $28.37) and bought $364,999,974 worth of shares (12,586,206 units at $29.00) (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    12/22/25 5:26:57 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Director Mills Andrew J. was granted 30,655 units of Class B Common Stock and bought $74,999,974 worth of shares (2,586,206 units at $29.00) (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    12/22/25 4:30:06 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Director Mills Charles N. was granted 64,005 units of Class B Common Stock and bought $74,799,990 worth of shares (2,579,310 units at $29.00) (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    12/22/25 4:30:04 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    6/1/26 6:16:21 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    6/1/26 6:05:43 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    6/1/26 4:15:05 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup resumed coverage on Medline with a new price target

    Citigroup resumed coverage of Medline with a rating of Buy and set a new price target of $60.00

    3/11/26 8:38:58 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Tigress Financial initiated coverage on Medline with a new price target

    Tigress Financial initiated coverage of Medline with a rating of Buy and set a new price target of $55.00

    2/5/26 10:03:24 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    BTIG Research reiterated coverage on Medline with a new price target

    BTIG Research reiterated coverage of Medline with a rating of Buy and set a new price target of $55.00 from $50.00 previously

    1/21/26 1:17:48 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medline's Prime Vendor model expands outside the United States

    Agreement with Mohawk Medbuy in Canada marks first-of-its-kind Prime Vendor relationship outside the U.S.NORTHFIELD, Ill., May 29, 2026 /PRNewswire/ -- Medline (NASDAQ:MDLN) announced that Medline Canada has signed its first Prime Vendor agreement in the country and is the first Medline Prime Vendor relationship outside the United States. The agreement is with Mohawk Medbuy (MMC), one of Canada's largest healthcare procurement organizations, to support warehouse and supply chain logistics for its hospitals in Southwestern Ontario and builds from best practices from similar agreements with hundreds of healthcare providers in the U.S.

    5/29/26 10:25:00 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Medline Inc. announces closing of upsized secondary offering of Class A common stock

    NORTHFIELD, Ill., May 28, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (NASDAQ:MDLN) ("Medline") announced today that it has closed its upsized secondary offering of 72,554,594 shares of Medline Inc.'s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the "Selling Stockholders") at a price to the public of $37.00 per share. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 10,883,189 shares of Medline's Class A common stock. Medline did not sell any shares of Class A common stock in the offering and did not recei

    5/28/26 4:30:00 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Medline announces participation in upcoming investor conferences

    NORTHFIELD, Ill., May 27, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline") (NASDAQ:MDLN) today announced that members of the executive leadership team will be participating in the following investor conferences. Mike Drazin, chief financial officer, and Amanda Laabs, chief product officer, are scheduled to present at the William Blair 46th Annual Growth Stock Conference in Chicago, IL, on Wednesday, June 3, 2026, at 3:40pm ET.Jim Boyle, chief executive officer, and Mike Drazin, chief financial officer, are scheduled to present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL, on Tuesday, June 9, 2026, at 10:40am ET. Webcasts of the presentations will be a

    5/27/26 7:30:00 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Financials

    Live finance-specific insights

    View All

    MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

    EscharEx® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million Conference Call Today, May 27, 2026, at 8:30 a.m. Eastern Time YAVNE, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update. "During the first quarter, we continued to advance both our strategic and operational priorities," said Ofer Gonen, Chief Execut

    5/27/26 7:00:00 AM ET
    $MDLN
    $MDWD
    Medical/Dental Instruments
    Health Care
    Medicinal Chemicals and Botanical Products

    Medline Reports First Quarter 2026 Results

    Net sales of $7.4 billion, an increase of 10.7%Net income of $239 million, a decrease of 25.8%Adjusted EBITDA1 of $776 million, a decrease of 10.6%Raising full year 2026 Organic Sales2 guidance range to 8.5% to 9.5% NORTHFIELD, Ill., May 06, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline" or the "Company") (NASDAQ:MDLN), the largest provider of medical-surgical ("med-surg") products and supply chain solutions serving all points of care3, today reported its operating results for the three months ended March 28, 2026. "We started 2026 with strong momentum—growing with our existing customers, executing implementations at scale and winning new customers," said Jim Boyle, chief executive off

    5/6/26 7:30:00 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Medline to report first quarter 2026 results on May 6, 2026

    NORTHFIELD, Ill., April 08, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline") (NASDAQ:MDLN) today announced that it plans to report first quarter 2026 financial results on Wednesday, May 6, 2026. A press release and supplemental materials will be issued before the market opens. The company will host a webcast and conference call at 9:30am ET/ 8:30am CT to discuss the financial results. Information about Medline's financial results, including a link to the live webcast, will be available on the Events page of Medline's Investor Relations website at ir.medline.com. A replay of the webcast will be available following the event through the same website. About MedlineMedline is the largest pr

    4/8/26 9:00:00 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care